# Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

> **NCT05617430** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 43 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** HAIC
- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab Biosimilar IBI305

## Key facts

- **NCT ID:** NCT05617430
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-02
- **Primary completion:** 2024-04
- **Final completion:** 2024-06
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617430, "Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05617430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*